PCRXPacira BioSciences, Inc.

Healthcare

$36.42+69% 1Y

$36.42

$19.1652 weeks$36.46

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but well above its own median P/E.

1 good, 1 to watch, 1 without data

What the price assumes~−7% a yearderived · Jun 30, 2026

Priced for a decline (~−7% a year). The price demands less than its three-year revenue growth of 4% a year, expectations look modest.

Vs its own P/E range72% above its own medianderived

Expensive vs its own history: P/E 104.1 vs a 60.4 median over 18 quarters (+72% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What PCRX's price assumes

Pacira BioSciences, Inc. trades at 104× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.

104

Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · 4.96× the median: the market pays up for this one

Price / sales: 1.37
Price / sales · as of 2026-Q2
Free cash flow yield: 12%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: −6.6%
Growth the price implies · The price pays for −6.6% free cash flow growth a year for a decade; the business has delivered +12% a year over the last three.

Details›

Price / bookas of 2026-Q2: 1.52
EV / EBIToperating margin 2.7%: the multiple describes the denominator: not meaningful
EV / salesas of 2026-Q2: 1.52
Healthcare median P/E503 names: 27.9
Drug Manufacturers - Specialty & Generic median P/E44 names: 21.0
Free cash flow, trailing twelve months: $180M
Market capitalisation39.9 million shares, counted Aug 3, 2026: $1.45B
3-year revenue growth: +3.7%
3-year free cash flow growth: +12%

What the market has paid for these earnings: 18 quarters of its own multiple × $0.35 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$7.44
Its own P/E history, median	$21.13
Its own P/E history, upper quartile	$40.55
52-week range	$19.16 – $36.45
Today	$36.42

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.